Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma - Results of a prospective multicentre controlled trial

European Journal of Haematology

Volumn 77, Issue 6, 2006, Pages 493-500

  Faber, Edgar ^a   Pytlík, Robert ^b   Slabý, Jiří ^c   Zapletalová, Jana ^d   Kozák, Tomáš ^c   Raida, Luděk ^a   Papajík, Tomáš ^a   Žikešová, Eva ^b,c   Marešová, Ivana ^a   Hamouzová, Marie ^b   Indrák, Karel ^a   Trněný, Marek ^b  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Autologous peripheral stem cell transplantation; Filgrastim; Granulocyte colony stimulating factor; Haematopoietic recovery; Malignant lymphoma

Indexed keywords

CARMUSTINE; CYTARABINE; ETOPOSIDE; MELPHALAN; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLEEDING; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT REJECTION; HODGKIN DISEASE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY DELAY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 33750619349     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00741.x     Document Type: Article

References (20)

1. VALTEAU-COUANET D, FAUCHER C, AUPERIN A, et al. Cost effectiveness of day 5 G-CSF (Lenograstim®) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Bone Marrow Transplant 2005;36:547-552.
2. SCHMITZ N, LJUNGMAN P, CORDONNIER C, et al. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double-blind, randomized trial. Bone Marrow Transplant 2004;34:955-962.
3. HORNEDO J, SOLA C, SOLANO C, LOPEZ JJ, ALONSO S, LLUCH A, OJEDA B, GARCIA-CONDE J, CORTÉS-FUNES H on behalf of the SOLTI Group. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period. Bone Marrow Transplant 2002;29:737-743.
4. DE AZEVEDO AM, NUCCI M, MAIOILINO A, VIGORITO AC, SIMOES BP, ARANHA FJP, TABAK DG, VOLTARELLI J, DE SOUZA CA. A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation. Bone Marrow Transplant 2002;29:745-751.
5. OJEDA E, GARCIA-BUSTOS J, AGUADO MJ, ARRIETA R, QUEVEDO E, JIMENEZ YUSTE V, CANALES M, HERNANDEZ-NAVARRO F. A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in adults. Bone Marrow Transplant 1999;24:601-607.
6. TRNĚNÝ M, SLABÝ J, VÁLKOVÁ V, APLTAUEROVÁ M, JELÍNEK J, MARINOV I, PROCHÁZKA B, KLENER P. Granulocyte-colony stimulating factor administration after autologous peripheral blood progenitor cell transplantion - a prospective randomized trial of 10 ug/kg starting day+1 vs 5 ug/kg starting day +7. Blood 1999;94(Suppl. 1):407b (abstract 5046).
7. KAWANO Y, TAKAUE Y, MIMAYA J, et al. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. Blood 1998;11:4040-4046.
8. BOLWELL BJ, POHLMAN B, ANDRESEN S, KALAYCIO M, GOORMASTIC M, WISE K, WAKELING A, DANNLEY R, OVERMOYER B. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant 1998;21:369-373.
9. BENCE-BRUCKLER I, BREDESON C, ATKINS H, MCDIARMID S, HAMELIN L, HOPKINS H, PERRY G, GENEST P, HUEBSCH L. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 1998;22:965-969.
10. CETKOVSKÝ P, KOZA V, JINDRA P, ŠKOPEK P, ŠVOJGROVÁ M. Individual criteria could be optimal for starting G-CSF application after autologous stem cell transplantation. Bone Marrow Transplant 1997;20:639-641.
11. LINCH DC, MILLIGAN DW, WINFIELD DA, et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 1997;99:933-938.
12. MCQUAKER IG, HUNTER AE, PACEY S, HAYNES AP, IQBAL A, RUSSELL NH. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997;15:451-457.
13. FAUCHER C, LE CORROLLER AG, CHABANNON C, NOVAKOVITCH G, MANONNI P, MOATTI JP, NOUYRIGAT P, MARANINCHI D, BLAISE D. Administration of G-CSF can be delayed after transplantation of autologous G-CSF primed blood stem cells: a randomized study. Bone Marrow Transplant 1996;17:533-536.
14. KLUMPP TR, MANGAN KF, GOLDBERG SL, PEARLMAN ES, MACDONALD JS. Granulocyte colony-stimulating factor accelerates neutrophil entgraftment following peripheral-blood stem-cell transplantation: a prospective randomized trial. J Clin Oncol 1995;13:1323-1327.
15. DEMIRER T, AYLI M, DAGLI M, et al. Influence of posttransplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. Br J Haematol 2002;118:1104-1111.
16. FABER E, KNOTKOVÁ R, ZAPLETALOVÁ J, DUŠKOVÁ L, KEMPNÁ J, KUJICKOVA J, PIKALOVA Z, TAUBER Z, INDRAK K. A single delayed application of G-CSF after autologous peripheral blood stem cell transplantation - a pilot study. In: BERDEL WE, JÜRGENS H, BÜCHNER TH, RITTER J, KIENAST J, VORMOOR J, eds. Transplantation in Hematology and Oncology II. Berlin: Springer Verlag, 2003:107-111.
17. MINEISHI S, SAITO T, KANDA Y, TANOSAKI R, TOBINAI K, TAKAUE Y. Delayed recovery of neutrophil counts after peripheral stem cell transplantation which improved with administration of a minimal dose of G-CSF: a case report. Jpn J Clin Oncol 2001;31:43-45.
18. OSMA MM, ORTUNO F, LOZANO ML, GOMEZ-ESPUCH J, AYALA F, SANCHEZ-SERRANO I, PEREZ-CEBALLOS E, MORALEDA JM, VICENTE V. Administration of post-autologous PBSCT rhG-CSF is associated with long-term low concentration of bone marrow hematopoietic progenitor cells. Bone Marrow Transplant 2001;27:1287-1292.
19. BENSINGER WI, APPELBAUM F, ROWLEY S, et al. Factors thet influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995;13:2547-2555.
20. BOLWELL B, GOORMASTIC M, DANNLEY R, ANDRESEN S, OVERMOYER B, MENDEZ Z, KALAYCIOGLU M, DEMARS D, WISE K, POHLMAN B. G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 μg/kg/day. Bone Marrow Transplant 1997;19:215-219.